Lipocine Inc. Files 8-K: Procedural Update
Ticker: LPCN · Form: 8-K · Filed: Mar 26, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, procedural
TL;DR
Lipocine filed an 8-K, standard SEC reporting.
AI Summary
Lipocine Inc. filed an 8-K on March 26, 2025, reporting on other events and financial statements. The filing does not contain specific details about new events, material agreements, or financial results, but rather serves as a procedural update and filing of exhibits.
Why It Matters
This filing indicates Lipocine Inc. is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This filing is a routine procedural update and does not disclose new material information that would inherently increase risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- March 26, 2025 (date) — Date of Earliest Event Reported
- 001-36357 (other) — Commission File Number
- Delaware (jurisdiction) — State of Incorporation
- 99-0370688 (other) — IRS Employer Identification Number
- 675 Arapeen Drive, Suite 202 (address) — Principal Executive Offices
- Salt Lake City, Utah 84108 (address) — Principal Executive Offices
- (801) 994-7383 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Lipocine Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and to file 'Financial Statements and Exhibits' as of March 26, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 26, 2025.
What is Lipocine Inc.'s Commission File Number?
Lipocine Inc.'s Commission File Number is 001-36357.
In which state is Lipocine Inc. incorporated?
Lipocine Inc. is incorporated in Delaware.
What is the address of Lipocine Inc.'s principal executive offices?
The address of Lipocine Inc.'s principal executive offices is 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 26, 2025 regarding Lipocine Inc. (LPCN).